The company’s flagship product, Ohtuvayre, has a unique mechanism that combines bronchodilation and anti-inflammation for COPD treatment, potentially addressing unmet medical needs in a market ...
The adjustment follows Verona Pharma's announcement of fourth-quarter sales for Ohtuvayre, which totaled approximately $36 million, unaudited. These figures surpassed both Truist Securities' estimate ...
Verona Pharma's Ohtuvayre, a novel COPD treatment, achieved $36 million in Q4 sales, indicating strong market interest and unmet need for new therapies. Despite aggressive pricing, Ohtuvayre's ...
The adjustment follows Verona Pharma's announcement of fourth-quarter sales for Ohtuvayre, which totaled approximately $36 million, unaudited. These figures surpassed both Truist Securities ...
3 Stocks to DOUBLE This Year The 10 Best Stocks to Own in 2023 7 Stocks to Buy and Hold Forever Verona Pharma’s CEO, David Zaccardelli, highlighted the successful launch of Ohtuvayre ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback